Bone scan had no role in the staging of 765 consecutive operable T1–2N0–1 breast cancer patients without skeletal symptoms

Breast cancer is the most frequent female cancer, especially in 'developed' countries. 30-85% of metastatic breast cancer patients will develop bone metastases during the course of the disease. The objective of this study was to evaluate the skeletal metastases in breast cancer patients by using Tc-99m MDP bone scan. A retrospective study was conducted on 425 consecutive female breast carcinoma patients referred for bone scan to Institute of Nuclear Medicine and Allied Sciences, Rajshahi from January 2015 to November 2017. Bone scan was performed by an intravenous bolus injection of 20 mCi Tc99m-MDP (technetium 99m methylenediphosphonate). Bone phase images were taken at three hours after injection of the radiotracer. Out of 425 patients, 290 patients (68.24%) had either normal bone scan or negative for skeletal secondaries and 135 patients (31.76%) were positive for skeletal metastases.Out of 135 positive bone scans 114 (84.44%) patients had multiple sites (two or more) and 21 (15.56%) patients had solitary site of bony involvement. Highest number of skeletal metastases was noted in thoraco-lumbar spine (81.48%). Other sites of metastases were in cervical spine (22.96%), pelvic bones (54.81%), ribs (40.74%), sternum (16.30%), scapula (19.26%), upper extremities (28.15%), lower extremities (36.30%), skull bone (12.60%) and clavicle (13.33%). Tc-99m MDP bone scan is very cost effective in comparison to other imaging modalities (CT, MRI, and PET) and play a major role in early detection of skeletal metastasis in breast cancer patients.Medicine Today 2018 Vol.30(2): 49-52

Download Full-text

Correlation between Bone Scan Findings and CA 153 in Patients with Carcinoma Breast

Bangladesh Journal of Nuclear Medicine ◽

10.3329/bjnm.v20i1.36850 ◽

2018 ◽

Vol 20 (1) ◽

pp. 24

Author(s):

Samira Sharmin ◽

Jasmine Ara Haque ◽

Md Mahbub Ur Rahman ◽

Hosne Ara Rahman ◽

Jamiul Hossain ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Correlation Coefficient ◽

Bone Scan ◽

Positive Relationship ◽

Breast Cancer Patients ◽

Carcinoma Breast ◽

Pearson’S Correlation Coefficient ◽

Pearson's Correlation ◽

Pearson's Correlation Coefficient

Objectives: Breast carcinoma is the most life threatening malignant condition in women. This malignant disease commonly metastasizes to bone. Carbohydrate antigen (CA) 15-3 is a circulating human breast cancer associated antigen used as a tumor marker in the screening of breast cancer patients for metastasis. The objective of this study was to compare the levels of CA 15-3 and bone scan findings in patients with breast cancer.Patients and Methods: This cross sectional study was carried out at Institute of Nuclear Medicine and Allied sciences, Mitford, Dhaka, from January 2015 to December 2015. A total of 75 diagnosed breast cancer patients were enrolled in this study. All of them underwent bone scan. The tumor maker CA 15-3 was compared with bone scan findings. Pearson’s correlation coefficient test was done to see the relationship between bone scan and CA 15-3.Results: Mean age of the patients was 47.60 ± 10.53 years (range 25 to 65 years). About half (49%) of the patients belong to the age group 50 years and above. Mean ± SD of CA 15-3 was 84.06 ± 104.60 U/ml (range from 10.12 to 395.30 U/ml). Out of 75 patients, 33 patients showed elevated CA 15-3 level, among them 42% had negative bone scan with mean ± SD CA 15-3 level 60.98 ± 9.95 U/ml (range 40.26-72.17 U/ml), 58% patients had positive bone scan with mean ± SD CA 15-3 level 246.23 ± 81.35U/ml (range 110-395.30 U/ml). CA 15-3 was within normal limit (range 10.20-30.10 U/ml) in 42 patients. Among them 29% patients had negative bone scan and 71% patients had positive bone scan. Pearson’s correlation coefficient test showed positive relationship (p = 0.001, r = 0.343) between CA 15-3 level and bone scan findings.Conclusion: The result of the study showed positive relationship between the bone scan findings and CA 15-3 level of carcinoma breast patients.Bangladesh J. Nuclear Med. 20(1): 24-26, January 2017

Download Full-text

Evaluation of new sclerotic bone metastases in breast cancer patients during treatment

Acta Radiologica ◽

10.1080/028418500127345019 ◽

2000 ◽

Vol 41 (2) ◽

pp. 178-182 ◽

Cited By ~ 7

Author(s):

I. Çiray ◽

G. Åström ◽

I. Andréasson ◽

T. Edekling ◽

J. Hansen ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Bone Scan ◽

Conventional Radiography ◽

World Health ◽

Breast Cancer Patients ◽

Who Criteria ◽

Bone Scans ◽

Sclerotic Lesions

Purpose: According to the World Health Organization (WHO) criteria for response of bone metastases to therapy, new lesions indicate progressive disease. We intended to prove that a new sclerotic lesion on conventional radiography may also be a sign of a positive therapeutic response in a previously undetectable lytic metastasis. Material and Methods: In a previous placebo-controlled clinical trial of clodronate (Ostac) therapy, 139 breast cancer patients with bone metastases underwent both conventional radiography and bone scan every 6 months for 2 years with 99mTc before and during clodronate treatment. WHO criteria were applied for therapy response evaluation. Results: In 24 patients, 52 new sclerotic lesions observed during therapy were selected for re-evaluation of conventional radiographs and bone scans. In 8 of the 24 patients, 17 of 52 new sclerotic lesions (33%) had showed positive uptake on previous bone scans. These lesions were possibly misinterpreted as new when applying WHO criteria. Conclusion: For better assessment of new sclerotic lesions during treatment, more sensitive techniques, e.g. bone scan, are needed as a complement to conventional radiography.

Download Full-text